Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 4Stomach Neoplasms 2Cardiovascular Diseases 2Recurrence 1Pulmonary Embolism 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Hemorrhage 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Blood Specimen Collection 32Surveys and Questionnaires 24Radiotherapy 12Gene Expression Profiling 12Drug Therapy 12Surgical Procedures, Operative 11Bronchoscopy 10Magnetic Resonance Spectroscopy 9Immunotherapy 9Immunohistochemistry 9Tomography, X-Ray Computed 8Specimen Handling 8Observation 8Amplified Fragment Length Polymorphism Analysis 8Polymerase Chain Reaction 7pembrolizumab 6Psychiatric Rehabilitation 6Interviews as Topic 6Carboplatin 6Thoracic Surgery, Video-Assisted 5Reverse Transcriptase Polymerase Chain Reaction 5Microarray Analysis 5Liquid Biopsy 5Chemoradiotherapy 5Bevacizumab 5durvalumab 4Therapeutics 4Paclitaxel 4Nivolumab 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Lung Neoplasms × Aspirin × Clear all
NCT03532698 2020-07-23

Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Unknown
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡